Home | Practice Areas | Transactions
Experience in this Practice Area:
- Obtaining an Australian patent for a private client and subsequently negotiating a license for the patent to an Australian telecommunications carrier.
- Representing a biomass-to-fuel conversion technology company, with respect to a license agreement with one of Japan’s largest corporations involved in the environmental, chemicals and food industries, for a territory that includes Japan, Thailand, Malaysia and Indonesia. This deal resulted in the world’s first commercial plant to produce cellulosic ethanol from wood construction waste.
- Representing multiple start-up companies (in technologies ranging from wind turbine power to biomass production) in developing and implementing patent strategies, including obtaining patent protection and negotiating licensing arrangements.
- Participating on the deal team representing the buyer in a $430 million purchase of a Major League Baseball team.
- Participating in the due diligence, documentation, and integration phases of multimillion-dollar acquisitions of start-up companies by multinational pharmaceutical companies.
- Representing a drug delivery company with respect to a licensing agreement, including manufacturing and distribution components with a major pharmaceutical company.
- Representing the global leader in grand-format printers with respect to its major sales, distribution, and development transactions, until the company was acquired for $281 million.
- Representing the licensees with respect to the preparation and negotiation of a license agreement for the worldwide development and commercialization of products.
- Preparing a sponsorship and intellectual property agreement between a research and development biotechnology company focused on tissue engineering and a major university.
- Participating in the due diligence, documentation, and integration phases of multimillion-dollar acquisitions of start-up companies by multinational pharmaceutical companies.
- Representing U.S. companies in agreements with foreign companies and governments.
- Representing a biopharmaceutical company in its exclusive worldwide licensing agreement with a global pharmaceutical company for the development and co-commercialization of a first-in-class, fully human monoclonal antibody in a deal worth up to $530M.
